CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

  • Current Quote
  • Stock Chart
$3.50 + 0.09 (2.64%)
Day High:$3.67
Day Low:$3.48
01/18/184:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345


Recent News

Jan 18, 2018CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®
SEATTLE, Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with... 
Printer Friendly Version
Nov 08, 2017CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference
SEATTLE, Nov. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the Jefferies 2017 London Healthcare Conference Wednesday, November 15, 2017 at 12:20 p.m. ET / 5:20 p.m. GMT in London. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutical company focused on ... 
Printer Friendly Version
Nov 06, 2017CTI BioPharma Reports Third Quarter 2017 Financial Results
-Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern time SEATTLE, Nov. 6, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the third quarter ended September 30, 2017. Recent Highlights    Clinical / Regulatory In July 2017, the first patient was enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. PAC203 is designed to eval... 
Printer Friendly Version


There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.